Patents by Inventor Anja Molhart Hog

Anja Molhart Hog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA Antagonist Compounds for the Modulation of MCL-1
    Publication number: 20100323967
    Abstract: Oligonucleotides directed against the Mcl-1 gene are developed for modulating the expression of Mcl-1 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding Mcl-1. Methods of using these compounds for modulation of Mcl-1 expression and for the treatment of diseases associated with over expression of Mcl-1 are provided. Examples of such diseases include cancer and systemic mastocytosis.
    Type: Application
    Filed: December 5, 2008
    Publication date: December 23, 2010
    Applicant: Santaris Pharma A/S
    Inventors: Jens Bo Rode Hansen, Anja Mølhart Høg
  • Oligomeric compounds for the modulation of HIF-1alpha expression
    Patent number: 7846911
    Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIP-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 7, 2010
    Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
  • Oligomeric compounds for the modulation HIF-1? expression
    Patent number: 7737264
    Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: June 15, 2010
    Assignees: Santaris Pharma A/S
    Inventors: Charlotte Albæk Thrue, Anja Mølhart Høg, Paul E. G. Kristjansen
  • OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1alpha EXPRESSION
    Publication number: 20100093839
    Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIP-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
    Type: Application
    Filed: October 15, 2009
    Publication date: April 15, 2010
    Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E.G. Kristjansen
  • Oligomeric compounds for the modulation HIF-1alpha expression
    Publication number: 20040096848
    Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1&agr; (HIF-1&agr;) gene are provided for modulating the expression of HIF-1&agr;. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1&agr;. Methods of using these compounds for modulation of HIF-1&agr; expression and for the treatment of diseases associated with the hypoxia-inducible factor-1&agr; are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
    Type: Application
    Filed: October 23, 2003
    Publication date: May 20, 2004
    Inventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E.G. Kristjansen